ENCOD
  • Donate
  • Covid-19 messages
  • News
  • Organisation
    • About us
    • Our Team
      • WORKING GROUPS
      • STUDIES
      • GENERAL ASSEMBLIES
      • FINANCES
    • Our Mission
    • FAQ
    • IN THE PRESS
    • ANNUAL REPORTS
    • ENCOD MEMBERS
    • INFO FOR MEMBERS
  • Join us
  • Actions & Events
    • CAMPAIGNS
      • FREEDOM TO FARM
        • FREEDOM TO FARM
        • FREEDOM TO FARM IS THE FIRST TEST OF RELIGIOUS FREEDOM
        • FREEDOM TO FARM AND CANNABIS SOCIAL CLUBS FOR PEOPLE WHO USE CANNABIS AS A MEDICINE
        • FREEDOM TO FARM POSTERS
        • FREEDOM TO FARM STICKERS
      • Cannabis Social Clubs
        • HOW TO CREATE A CANNABIS SOCIAL CLUB
        • EXAMPLES OF CSC’S IN EUROPE
        • Cannabis Social Clubs in Aktion
        • PROPOSAL TO REGULATE THE SELF CULTIVATION AND CANNABIS SOCIAL CLUBS IN BELGIUM
        • Catalonia regulates the Cannabis Social Clubs
        • WORKSHOP ‘HOW TO SET UP A CSC IN GERMANY’
      • 2017
      • 2014
      • 2010 – 2013
      • 2009
      • 2008
      • 2007
      • 2006
      • 1995 – 2005
      • EU LOBBY CAMPAIGN
        • 2011
        • 2010
        • 2009
        • 2008
        • 2007
        • 2006
        • 2005
        • 2004
    • ACTION APPEALS
  • Bulletins
  • Video Archive
  • Donate
  • Covid-19 messages
  • News
  • Organisation
    • About us
    • Our Team
      • WORKING GROUPS
      • STUDIES
      • GENERAL ASSEMBLIES
      • FINANCES
    • Our Mission
    • FAQ
    • IN THE PRESS
    • ANNUAL REPORTS
    • ENCOD MEMBERS
    • INFO FOR MEMBERS
  • Join us
  • Actions & Events
    • CAMPAIGNS
      • FREEDOM TO FARM
        • FREEDOM TO FARM
        • FREEDOM TO FARM IS THE FIRST TEST OF RELIGIOUS FREEDOM
        • FREEDOM TO FARM AND CANNABIS SOCIAL CLUBS FOR PEOPLE WHO USE CANNABIS AS A MEDICINE
        • FREEDOM TO FARM POSTERS
        • FREEDOM TO FARM STICKERS
      • Cannabis Social Clubs
        • HOW TO CREATE A CANNABIS SOCIAL CLUB
        • EXAMPLES OF CSC’S IN EUROPE
        • Cannabis Social Clubs in Aktion
        • PROPOSAL TO REGULATE THE SELF CULTIVATION AND CANNABIS SOCIAL CLUBS IN BELGIUM
        • Catalonia regulates the Cannabis Social Clubs
        • WORKSHOP ‘HOW TO SET UP A CSC IN GERMANY’
      • 2017
      • 2014
      • 2010 – 2013
      • 2009
      • 2008
      • 2007
      • 2006
      • 1995 – 2005
      • EU LOBBY CAMPAIGN
        • 2011
        • 2010
        • 2009
        • 2008
        • 2007
        • 2006
        • 2005
        • 2004
    • ACTION APPEALS
  • Bulletins
  • Video Archive
September 24, 2009  |  By ENCOD In 2009

ON THE THERAPEUTIC USE OF IBOGA

arton1969

Iboga


History

Ibogaine is a psychoactive alkaloid naturally occurring in the root bark of the West African shrub iboga. While ibogaine is a mild stimulant in small doses, in larger doses it induces a profound psychedelic state. Historically, it has been used in healing ceremonies and initiations by members of the Bwiti religion in various parts of West Africa. Since 1960 it has been administered in the western world to people with problem substance use. Reduction of withdrawal symptoms have recently been reported and a temporary elimination of substance-related cravings.


Reports on therapeutic use

Iboga and ibogaine are used to treat opiate, stimulant, alcohol and nicotine dependence as well as other psychological disorders.

In 2005 it was reported that ibogaine expresses the growth factor GDNF — glial cell derived neurotrophic factor – and that GDNF not only regenerates damaged dopamine neurons, but back-signals to the cell nuclei to express more GDNF. The idea is that in this way, a benign, self-sustaining loop is established that obviates the need for artificial elevation of dopamine levels and persists without administration of additional ibogaine.

Recently positive anti-viral and immune-modulatory effects have been reported in the treatment of hepatitis C, herpes simplex, asthma, and even multiple sclerosis.


Legal status

In some countries (USA, UK, France) iboga is prohibited. Meanwhile, some 30-40 clinics or solo practicians around the world are administering ibogaine, mostly for the treatment of addiction.

In the absence of large doubly-blinded, randomized clinical trials of ibogaine for treatment of substance dependence, access to ibogaine which is now unregulated, but condoned in a few countries, is actually threatened.

Before ibogaine can be made available as a regular medication. clinical trials are necessary. Both public entities and pharmaceutical companies have refused to invest in such clinical research until now. It is unclear why some practitioners of maintenance therapies support this resistance to research.

We call upon the international harm reduction movement to eschew any role in the further banning of ibogaine access or research into its use against addiction and diseases such as hepatitis C, which currently kills more people in the advanced world than AIDS.

Naturally, we encourage proper observance of safety measures. But good clinical data can be obtained, even in the absense of placebo-controlled, randomized trials, by careful longitudinal record-keeping of ibogaine after-effects, which prohibition discourages.


Risks

The dissemination of safety information to treatment providers worldwide virtually eliminated adverse medical events in 2008-9.

Given its particular effects there is little chance that iboga will be used recreationally.


More information

[
Ibogaine.org->http://www.ibogaine.org/]

Multidisciplinary Association for Psychedelic Studies

The Ibogaine Research Project


More information on the therapeutic use of other psycho-active substances

Previous StoryON THE THERAPEUTIC USE OF COCA LEAVES AND COCAINE
Next StoryON THE THERAPEUTIC USE OF LSD

Related Articles

  • arton2192
    PRAGUE DEPENALISES USE OF ALL DRUGS
  • arton2187
    DRUG MONEY HELPED SAVE BANKS, SAYS UN DRUG TSAR

Categories

Archives

  • About us
  • Downloads
  • Contact
  • Privacy Policy
  • Legal Notice & Terms of Use
  • Imprint

Copyright ©2018 ThemeFuse. All Rights Reserved

We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking “Accept All”, you consent to the use of ALL the cookies. However, you may visit "Cookie Settings" to provide a controlled consent.
Cookie SettingsAccept All
Manage consent

Privacy Overview

This website uses cookies to improve your experience while you navigate through the website. Out of these, the cookies that are categorized as necessary are stored on your browser as they are essential for the working of basic functionalities of the website. We also use third-party cookies that help us analyze and understand how you use this website. These cookies will be stored in your browser only with your consent. You also have the option to opt-out of these cookies. But opting out of some of these cookies may affect your browsing experience.
Necessary
Always Enabled
Necessary cookies are absolutely essential for the website to function properly. These cookies ensure basic functionalities and security features of the website, anonymously.
CookieDurationDescription
cookielawinfo-checkbox-analytics11 monthsThis cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Analytics".
cookielawinfo-checkbox-functional11 monthsThe cookie is set by GDPR cookie consent to record the user consent for the cookies in the category "Functional".
cookielawinfo-checkbox-necessary11 monthsThis cookie is set by GDPR Cookie Consent plugin. The cookies is used to store the user consent for the cookies in the category "Necessary".
cookielawinfo-checkbox-others11 monthsThis cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Other.
cookielawinfo-checkbox-performance11 monthsThis cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Performance".
viewed_cookie_policy11 monthsThe cookie is set by the GDPR Cookie Consent plugin and is used to store whether or not user has consented to the use of cookies. It does not store any personal data.
Functional
Functional cookies help to perform certain functionalities like sharing the content of the website on social media platforms, collect feedbacks, and other third-party features.
Performance
Performance cookies are used to understand and analyze the key performance indexes of the website which helps in delivering a better user experience for the visitors.
Analytics
Analytical cookies are used to understand how visitors interact with the website. These cookies help provide information on metrics the number of visitors, bounce rate, traffic source, etc.
Advertisement
Advertisement cookies are used to provide visitors with relevant ads and marketing campaigns. These cookies track visitors across websites and collect information to provide customized ads.
Others
Other uncategorized cookies are those that are being analyzed and have not been classified into a category as yet.
SAVE & ACCEPT

REPUBLISHING TERMS

You may republish this article online or in print under our Creative Commons license. You may not edit or shorten the text, you must attribute the article to ENCOD and you must include the author’s name in your republication.

If you have any questions, please email thujer@gmail.com

License

Creative Commons License AttributionCreative Commons Attribution
ON THE THERAPEUTIC USE OF IBOGA